×

What are you searching for?




Healthcare

4 Min read

Boehringer Ingelheim gets an injunction against sale of Empagliflozin

Published On 27 Oct 2021 11:36 AM


SHARE THIS ARTICLE  


Boehringer Ingelheim, a MNC firm has obtained two separate interim injunctions against Dr Reddy’s and MSN Labs for selling their versions of Empagliflozin, an anti-diabetes drug in India. Both these pharma companies have recently launched a low-priced version of the anti-diabetes drug, Empagliflozin.

Highlights

Leave a comment 

comments (0)